Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals Plc    HIK   GB00B0LCW083

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : receives approval for Sodium Oxybate Oral Solution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/19/2017 | 04:04pm CET

Release date- 18012017 - London- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its wholly owned US subsidiary, Roxane Laboratories, Inc. (Roxane), has received an approval from the US Food and Drug Administration for its Sodium Oxybate Oral Solution, 500 mg/mL, the generic equivalent to Xyrem.

Roxane's Sodium Oxybate Oral Solution is indicated for the treatment of cataplexy (sudden loss of muscle strength) and excessive daytime sleepiness in patients with narcolepsy.

Roxane is currently involved in patent litigation concerning this product in the US District Court for the District of New Jersey.

Roxane was the first ANDA applicant to submit a substantially complete ANDA with paragraph IV certification for Sodium Oxybate Oral Solution, 500 mg/mL and therefore is eligible for 180 days of generic drug exclusivity following the launch of its product.

In its 2015 Annual Report, Jazz Pharmaceuticals PLC reported net sales of Xyrem of approximately $955 million in 2015.

Important safety information:

Sodium Oxybate is a central nervous system (CNS) depressant and has caused changes in alertness (or consciousness) and trouble breathing (respiratory depression). Call your doctor right away if you have any of these serious side effects. These effects happened even when Sodium Oxybate was given in recommended doses. In studies, almost all of the patients with narcolepsy who were given Sodium Oxybate were also taking medication to help them stay awake during the day.

Sodium Oxybate is a form of gamma hydroxybutyrate (GHB). Abuse of GHB, either alone or in combination with other drugs that cause changes in alertness (or consciousness), has caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), very low levels of alertness (consciousness), coma, and death.

Because of these risks, Roxane's Sodium Oxybate will be available only through the Sodium Oxybate REMS Program. Prescribers and patients must enroll in the program.

Do not take Sodium Oxybate if you take other sleep medicines or sedatives (medicines that cause sleepiness), drink alcohol, or have a rare problem called semialdehyde dehydrogenase deficiency.

Sodium Oxybate is a controlled substance (CIII) because it can be a target for people who abuse prescription medicines or street drugs. Never give your Sodium Oxybate to anyone else because it may cause death or harm them. Selling or giving this medication away is against the law.

Do not drive a car, use heavy machinery, fly an airplane, or do anything that is dangerous or that requires you to be fully awake for at least 6 hours after you take Sodium Oxybate. You should not do these activities until you know how Sodium Oxybate affects you.

Sodium Oxybate can cause serious side effects, including the following:

Breathing problems, including slower breathing, trouble breathing, and or/short periods of not breathing while sleeping (sleep apnea). People who already have breathing or lung problems have a higher chance of having breathing problems when they use Sodium Oxybate.

Mental health problems, including confusion, seeing or hearing things that are not real (hallucinations), unusual or disturbing thoughts (abnormal thinking), feeling anxious or upset, depression, or thoughts of killing yourself or trying to kill yourself. Call your doctor right away if you have symptoms of mental health problems.

Sleepwalking. Sleepwalking can cause injuries. Call your doctor if you start sleepwalking. Your doctor should check you.

Tell your doctor if you are on a salt-restricted diet or if you have high blood pressure, heart failure, or kidney problems. Sodium Oxybate contains a lot of sodium (salt) and may not be right for you.

The most common side effects of Sodium Oxybate include nausea, dizziness, vomiting, bedwetting, and diarrhea. Your side effects may increase when you take higher doses of Sodium Oxybate. Sodium Oxybate can cause physical dependence and craving for the medication when it is not taken as directed. These are not all the possible side effects of Sodium Oxybate.

Before you take Sodium Oxybate, tell your doctor if you are:

Pregnant or planning to become pregnant. It is not known if Sodium Oxybate can harm your unborn baby.

Breastfeeding or plan to breastfeed. It is not known if Sodium Oxybate passes into your breast milk. You and your doctor should decide if you will take Sodium Oxybate or breastfeed.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS PLC
01/19 HIKMA PHARMACEUTICALS : receives approval for Sodium Oxybate Oral Solution
01/18 HIKMA PHARMACEUTICALS : Gets US Approval For Generic Cataplexy Drug
01/17 HIKMA PHARMACEUTICALS : *jefferies raises hikma pharmaceutical price target to 2..
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/11 HIKMA PHARMACEUTICALS : Pharmaceutical company to support KACE's next award cere..
01/04 HIKMA PHARMACEUTICALS : *jpmorgan cuts hikma pharmaceutical pt to 2100 pence - '..
2016 British FTSE 100 decreases 0.04%
2016 British FTSE 100 rises 0.38% on Tuesday
2016 British FTSE 100 edges up slightly Monday
More news
Sector news : Pharmaceuticals - NEC
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2016 Emerging Markets Shake Off Brexit
2016 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2016 Results - Earning..
2016 Hikma Pharmaceuticals reports H1'16 results
2016 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q4 2015 Results - Earning..
2016 Hikma Pharmaceuticals reports FY'15 results
Advertisement
Financials ($)
Sales 2016 1 961 M
EBIT 2016 364 M
Net income 2016 157 M
Debt 2016 630 M
Yield 2016 0,88%
P/E ratio 2016 31,61
P/E ratio 2017 18,45
EV / Sales 2016 3,24x
EV / Sales 2017 2,72x
Capitalization 5 715 M
More Financials
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals Plc Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 28,3 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Saaid Samih Taleb Darwazah Chairman & Chief Executive Officer
Khalid Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Ragheb Al-Shakhshir Vice President-Research & Development
Michael Richard Dwyer Ashton Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS ..3.33%5 715
JOHNSON & JOHNSON-0.88%310 685
ROCHE HOLDING LTD.1.29%200 208
PFIZER INC.-2.40%192 367
NOVARTIS AG-3.71%185 489
MERCK & CO., INC.2.48%166 338
More Results